308 related articles for article (PubMed ID: 33214036)
21. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
23. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
[TBL] [Abstract][Full Text] [Related]
25. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
28. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
31. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation.
Abdallah AE; Eissa SI; Al Ward MMS; Mabrouk RR; Mehany ABM; El-Zahabi MA
Bioorg Chem; 2021 Apr; 109():104695. PubMed ID: 33647743
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
34. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
35. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
36. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
37. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
39. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors.
Atta-Allah SR; AboulMagd AM; Farag PS
Bioorg Chem; 2021 Jul; 112():104923. PubMed ID: 33932767
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
